B
Brendan M. Weiss
Researcher at Janssen Pharmaceutica
Publications - 127
Citations - 11613
Brendan M. Weiss is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Multiple myeloma & Population. The author has an hindex of 36, co-authored 122 publications receiving 8977 citations. Previous affiliations of Brendan M. Weiss include National Institutes of Health & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport,Edward A. Stadtmauer,Gwendolyn Binder-Scholl,Olga Goloubeva,Dan T. Vogl,Simon F. Lacey,Ashraf Badros,Alfred L. Garfall,Brendan M. Weiss,Jeffrey Finklestein,Irina Kulikovskaya,Sanjoy K. Sinha,Shari Kronsberg,Minnal Gupta,Sarah Bond,Luca Melchiori,Joanna E. Brewer,Alan D. Bennett,Andrew B. Gerry,Nicholas J. Pumphrey,Daniel Williams,Helen K. Tayton-Martin,Lilliam Ribeiro,Tom Holdich,Saul Yanovich,Nancy M. Hardy,Jean A. Yared,Naseem Kerr,Sunita Philip,Sandra Westphal,Don L. Siegel,Bruce L. Levine,Bent K. Jakobsen,Michael Kalos,Carl H. June +34 more
TL;DR: NY-ESO-1–LAGE-1 TCR–engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma, according to the expected mechanism of action of the transferred T cells.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Journal ArticleDOI
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall,Marcela V. Maus,Wei-Ting Hwang,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Zhaohui Zheng,Dan T. Vogl,Adam D. Cohen,Brendan M. Weiss,Karen Dengel,Naseem Kerr,Adam Bagg,Bruce L. Levine,Carl H. June,Edward A. Stadtmauer +15 more
TL;DR: A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy and autOLOGous stem-cell transplantation, which led to a complete response.